nevirapine has been researched along with Acute Hepatic Failure in 6 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We describe a detailed case of fulminant hepatitis induced by nevirapine (Viramune) and treated by liver transplantation." | 7.73 | Liver transplantation for fulminant hepatitis related to nevirapine therapy. ( Antonini, T; Buyse, S; Castaing, D; Duclos-Vallée, JC; Ichai, P; Samuel, D; Sebagh, M; Vibert, E, 2006) |
| " The one adverse event associated with nelfinavir occurred in a subject with a CD4 cell count less than 250 cells/microL." | 6.71 | Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. ( Baker, D; Foca, M; Frenkel, LM; Gandia, J; Gonzalez-Garcia, A; Hitti, J; Huang, S; McNamara, J; Nachman, SA; Paul, ME; Provisor, A; Stek, AM; Stevens, LM; Thorpe, EM; Watts, DH; Wei, LJ, 2004) |
| "We describe a case of nevirapine-induced Stevens-Johnson Syndrome (SJS) and fulminant hepatic failure (FHF) requiring liver transplantation." | 3.76 | Nevirapine-induced stevens johnson-syndrome and fulminant hepatic failure requiring liver transplantation. ( del Rio Martin, J; Fiel, MI; Huprikar, S; Jao, J; Schiano, T; Sturdevant, M, 2010) |
| " We describe a detailed case of fulminant hepatitis induced by nevirapine (Viramune) and treated by liver transplantation." | 3.73 | Liver transplantation for fulminant hepatitis related to nevirapine therapy. ( Antonini, T; Buyse, S; Castaing, D; Duclos-Vallée, JC; Ichai, P; Samuel, D; Sebagh, M; Vibert, E, 2006) |
| " The one adverse event associated with nelfinavir occurred in a subject with a CD4 cell count less than 250 cells/microL." | 2.71 | Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. ( Baker, D; Foca, M; Frenkel, LM; Gandia, J; Gonzalez-Garcia, A; Hitti, J; Huang, S; McNamara, J; Nachman, SA; Paul, ME; Provisor, A; Stek, AM; Stevens, LM; Thorpe, EM; Watts, DH; Wei, LJ, 2004) |
| " One patient erroneously took double dosing of nevirapine, while the other patient did not attend the scheduled laboratory control two weeks after the initiation of nevirapine treatment." | 1.33 | [Hepatic failure due to nevirapine treatment for HIV infection]. ( Katzenstein, TL; Mens, H, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jao, J | 1 |
| Sturdevant, M | 1 |
| del Rio Martin, J | 1 |
| Schiano, T | 1 |
| Fiel, MI | 1 |
| Huprikar, S | 1 |
| Hitti, J | 1 |
| Frenkel, LM | 1 |
| Stek, AM | 1 |
| Nachman, SA | 1 |
| Baker, D | 1 |
| Gonzalez-Garcia, A | 1 |
| Provisor, A | 1 |
| Thorpe, EM | 1 |
| Paul, ME | 1 |
| Foca, M | 1 |
| Gandia, J | 1 |
| Huang, S | 1 |
| Wei, LJ | 1 |
| Stevens, LM | 1 |
| Watts, DH | 1 |
| McNamara, J | 1 |
| Mens, H | 1 |
| Katzenstein, TL | 1 |
| Buyse, S | 1 |
| Vibert, E | 1 |
| Sebagh, M | 1 |
| Antonini, T | 1 |
| Ichai, P | 1 |
| Castaing, D | 1 |
| Samuel, D | 1 |
| Duclos-Vallée, JC | 1 |
| Maniar, JK | 1 |
| Shah, SR | 1 |
| Verma, R | 1 |
| Kamath, R | 1 |
| Gupte, P | 1 |
| Maniar, A | 1 |
| Sha, BE | 1 |
| Proia, LA | 1 |
| Kessler, HA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Trial of Protease Inhibitor-Including vs. Protease Inhibitor-Sparing Regimens for Women Who Initiate Therapy of HIV Infection During Pregnancy[NCT00017719] | Phase 3 | 440 participants | Interventional | 2002-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for nevirapine and Acute Hepatic Failure
| Article | Year |
|---|---|
Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Inf | 2004 |
5 other studies available for nevirapine and Acute Hepatic Failure
| Article | Year |
|---|---|
Nevirapine-induced stevens johnson-syndrome and fulminant hepatic failure requiring liver transplantation.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Hemofiltration; HIV Infections; Huma | 2010 |
[Hepatic failure due to nevirapine treatment for HIV infection].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Fatal Outcome; Female; HIV Seropositi | 2005 |
Liver transplantation for fulminant hepatitis related to nevirapine therapy.
Topics: Adult; Anti-HIV Agents; Female; Hepatitis; HIV Infections; HIV-1; Humans; Liver Failure, Acute; Live | 2006 |
Nevirapine-induced fulminant hepatitis.
Topics: Adult; Anti-Retroviral Agents; Fatal Outcome; HIV Infections; Humans; Liver Failure, Acute; Male; Ne | 2006 |
Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Female; H | 2000 |